CMR Imaging, NT-proBNP Improve Risk Prediction in Hypertrophic Cardiomyopathy

Why It Matters

Enhanced risk stratification can curb unnecessary implantable cardioverter‑defibrillator implants while ensuring high‑risk patients receive timely intervention, optimizing outcomes and healthcare resources.

Key Takeaways

• LGE percentage strongly predicts adverse HCM outcomes, HR 1.86 per 10% increase
• NT‑proBNP levels add independent prognostic value to imaging metrics
• New model reaches C‑index 0.77, outperforming current SCD risk scores
• LGE ≥9% of LV mass identifies a high‑risk subgroup
• Genetic data contributed little compared to imaging and biomarkers

Pulse Analysis

Hypertrophic cardiomyopathy remains a leading cause of sudden cardiac death, yet existing guideline tools focus narrowly on arrhythmic risk and often miss patients who would benefit from an implantable cardioverter‑defibrillator (ICD). Clinicians have long grappled with the trade‑off between over‑treating low‑risk individuals and under‑detecting those poised for adverse events. This tension underscores a broader shift toward precision cardiology, where detailed phenotypic data can refine therapeutic decisions.

The HCMR investigators leveraged a multinational cohort of nearly 2,700 patients to test whether cardiac magnetic resonance (CMR) imaging and the biomarker NT‑proBNP could close this predictive gap. Late gadolinium enhancement (LGE) quantifies myocardial fibrosis, and the study showed a near‑doubling of risk for each 10‑point rise in LGE percentage. Coupled with elevated NT‑proBNP, left‑ventricular mass index, and prior heart‑failure history, these variables produced a prognostic model with a C‑index of 0.77—significantly higher than traditional SCD scores. Notably, genetic markers, while valuable for diagnosis, contributed little to outcome prediction in this analysis.

If validated in future trials, integrating CMR scar assessment and NT‑proBNP into routine HCM work‑ups could transform clinical pathways. Physicians would have a more nuanced risk spectrum, allowing selective ICD placement and intensified monitoring for those with extensive fibrosis or high biomarker levels. Such an approach promises to reduce procedural costs, minimize patient exposure to unnecessary device complications, and ultimately improve survival. The study also exemplifies the growing role of multimodal imaging and circulating biomarkers in cardiovascular risk modeling, a trend likely to expand across other cardiomyopathies.